Ovarian Cancer

The seven-time Olympic medalist found strength in her competitive spirit through cancer.

I’m running this marathon to win it. I want to say don’t let a wall stop you; keep running, keep fighting!

A second ovarian cancer recurrence in three years prompted this review of lessons learned. If I could go back three and a half years and give advice to my newly diagnosed self, what would I say?

Patients with ovarian cancer tend to underreport their most challenging symptoms; however, an analysis of their online comments could give health care providers insight into how to help.

Despite increased physical activity, nutritional intake behavior among female cancer survivors did not improve with an exercise intervention program, according to a randomized-controlled trial.

An expert discusses the exciting new developments extending survival in the evolving ovarian cancer treatment space.

A young advocate emphasizes the importance of communication between parents and their children about an ovarian cancer diagnosis.

A gynecologic-oncology clinical nurse specialist and one of this year’s CURE Ovarian Cancer Heroes discussed the lack of resources for patients with ovarian cancer and the need for more research.

We've got a sneak peek at what’s inside CURE®'s Women’s Cancers issue.

Patients speak up on the rarely discussed side effects of gynecologic cancers.

Women with this disease are living longer, despite common recurrence.

An endometrial cancer survivor runs to raise awareness for a disease many don’t want to talk about.

Cancer isn’t black and white, nor is it predictable. A diagnosis and the subsequent treatment of the many varieties of this complex disease can be challenging because of gray areas and uncertainties.

The “Whiskey Cavalier” actor opens up about caregiving for his mother following her ovarian cancer diagnosis.

This week, we spoke with all three of CURE’s 2019 Ovarian Cancer Heroes: Ryan Mitstifer Walton, Paula Anastasia, RN, MN, AOCN, and Shannon Westin, M.D., M.P.H.

Researchers define the genetic characteristics of ovarian tumors-- information that could lead to new opportunities for personalized therapy and may explain why screening programs for the disease haven’t been successful.

Ten years later, a woman with a BRCA1 mutation finally feels more like herself.

Understand how the rare relative of ovarian cancer is diagnosed and treated.

Did we bring this scary, painful, financially draining monster into our lives by eating too many cookies and not doing enough jumping jacks? We need a reliable diagnostic screening tool for ovarian cancer and we need it now.

In this week’s episode, we spoke with the most decorated Olympic gymnast and ovarian cancer survivor Shannon Miller before CURE’s second annual Ovarian Cancer Heroes gala.

Lenvima (lenvatinib) in combination with weekly paclitaxel induced activity among those with recurrent endometrial and platinum-resistant epithelial ovarian cancer, according to results from a phase I study.

Treatment with the combination of Keytruda (pembrolizumab), Avastin (bevacizumab) and metronomic cyclophosphamide appeared safe and effective in women with recurrent epithelial ovarian cancer, according to results from an open-label phase 2 study.

Prior exposure to PARP inhibitor treatment may not lead to resistance in future use with these agents in women with recurrent epithelial ovarian cancer, meaning repeat use could become more common.

Side effects decreased among patients with high-risk ovarian cancer who received an individualized starting dose of Zejula (niraparib), based upon baseline bodyweight and platelet counts, compared with a fixed starting dose.

Patients with recurrent ovarian cancer who received Zejula (niraparib) maintenance therapy experienced longer progression-free survival, as well as more time without symptoms or toxicity compared with placebo, according to results from the phase 3 ENGOT-OV16/NOVA trial.